Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Merck CFO: we’re not only about Keytruda

Highlighted the continued growth of other key cancer drugs

- PMLiVE

Sanofi/Regeneron wins another EU approval for Dupixent

Becomes first biologic approved in EU for CRSwNP indication

Roche Basel Switzerland

US, EU regulators start review of Roche’s Soliris rival satralizumab

Sets up a possible market clash with Alexion next year

UK vs US: what makes a successful immunisation programme?

Emily Macdonald calls on her experience as a public health nurse specialising in the prevention of infectious disease in both the US and UK, to explore the differences between immunisation...

Blue Latitude Health

- PMLiVE

Delivering the promise of regenerative medicine

By Rich Quelch

- PMLiVE

Bedrock are in the Top 3

Bedrock named No. 3 Young Agency by PMLive

Bedrock Healthcare Communications

- PMLiVE

GSK takes new-class antibiotic into phase 3 for serious infections

Could provide a much-needed option for treatment-resistant infections

Are we ready for an Alzheimer’s disease modifying treatment

Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. But if a new therapy entered the market today, would healthcare systems be ready for...

Blue Latitude Health

- PMLiVE

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

Therapy candidate was licensed in a $1bn-plus deal last year

- PMLiVE

GSK’s pivotal TB vaccine could prevent millions of deaths

Key study took place in TB-endemic regions, testing 3,500 participants

- PMLiVE

AZ’s Imfinzi combo scores in front-line lung cancer

Attempts to catch up to BMS and Merck in non-small cell lung cancer

- PMLiVE

Healthcare’s voice revolution

With the UK’s NHS unveiling a major partnership with Amazon’s Alexa, is pharma in danger of being left behind?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links